ETR:SAZ STADA Arzneimittel Aktiengesellschaft (SAZ) Stock Price, News & Analysis €80.40 0.00 (0.00%) As of 11/27/2018 Add Compare Share Share Stock Analysis Stock Analysis About STADA Arzneimittel Aktiengesellschaft Stock (ETR:SAZ) Get SAZ alerts:Sign Up Key Stats Today's Range€79.56▼€80.9850-Day Range€80.40▼€80.4052-Week Range€53.41▼€80.98Volume92,068 shsAverage Volume51,761 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. Read More Receive SAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAZ Stock News HeadlinesCapVest to acquire majority stake in Stada, ending German firm's IPO plansSeptember 2, 2025 | msn.comCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyJuly 28, 2024 | stockhouse.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 8 at 1:00 AM | Porter & Company (Ad)IPO/Kreise: Stada-Eigner bereden erneuten Börsengang und VerkaufsoptionenApril 11, 2024 | finanznachrichten.deIPO/Kreise: Stada-Eigner bereden erneuten Börsengang und VerkaufsoptionenApril 11, 2024 | finanznachrichten.deArzneihersteller Stada hat Russland-Geschäft abgespaltenDecember 27, 2023 | finanznachrichten.deBayerische Motoren Werke Aktiengesellschaft 2023 Q3 - Results - Earnings Call PresentationNovember 5, 2023 | seekingalpha.comBasler Aktiengesellschaft (ETR:BSL) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportApril 8, 2023 | finance.yahoo.comSee More Headlines SAZ Stock Analysis - Frequently Asked Questions How have SAZ shares performed this year? STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2026. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40. What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Volkswagen (VOW3), Andersons (ANDE), Nuwellis (CHFS) and Chemed (CHE). Industry, Sector and Symbol Stock ExchangeETR SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolETR:SAZ CIKN/A Webwww.stada.de Phone+49-6101-6030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (ETR:SAZ) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersSpaceX Was Overvalued. This Asset Isn't.SpaceX lost 26% of its value in days, wiping out $50 billion of Elon Musk's net worth. Morningstar had flagged...Preserve Gold | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredForget SpaceX, Elon Is Now Powering the Next Hot IPOElon Musk is backing a new AI startup that's quietly growing faster than Tesla, SpaceX, and reportedly 23 time...Brownstone Research | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share STADA Arzneimittel Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.